Patient Study Brochures

NRG Oncology has created study brochures (linked below) specific to certain NRG Oncology studies that are open to patient enrollment. These pages include overview information on the specific study and frequently asked questions associated with the study. Please print these brochures for you and your doctor’s consideration when discussing your treatment.

Always Speak to Your Provider Regarding Decisions Pertaining to Your Healthcare
Please note that the goal of these materials is to educate and inform about NRG Oncology trials. The information available on our website is not a substitute for medical advice. Your healthcare team is the best source for information about your treatment options, including cancer clinical trials. Please take any information you collect to your doctor to discuss your questions and concerns. 

Participating sites should note that the Central Institutional Review Board (CIRB) has approved this material.

Study Brochures

Brain Tumors

NRG-BN003: Can Radiation Therapy Following Surgery Improve Outcomes for Grade II Meningioma? (NCT03180268)

NRG-BN005: Could Proton Therapy Benefit Patients with Brain Tumors? (NCT03180502)

NRG-BN007: Can Immune Therapy Help Extend the Life of People with a Glioblastoma (Brain Tumor)? (NCT04396860)

NRG-BN009: Can Adding Whole Brain Radiation Therapy that Avoids the Hippocampus to Stereotactic Radiosurgery Extend the Life and Improve Outcomes for People with Brain Cancer that has Spread After Previous Treatment with Stereotactic Radiosurgery (NCT04588246)

NRG-BN010: Can Adding the Immune Therapy Drugs Tocilizumab and Atezolizumab to Radiation Therapy Shrink or Stabilize Brain Cancer (Glioblastoma) that has Come Back after Initial Treatment

NRG-BN011: Can a Second Chemotherapy Drug in Addition to Standard Radiation and Temozolomide Extend Your Life or Prevent the Growth and Spread of Your Brain Tumor?

NRG-BN012: Comparing the addition of radiation either before or after surgery for patients with brain metastases

Breast Cancer

NRG-BR007: The DEBRA Study: Testing the usual treatment of radiation therapy and hormonal therapy for breast conserving treatment to hormonal therapy alone for low-risk, early stage breast cancer (NCT04852887)

NRG-BR008: The HERO Study: Testing the usual treatment of radiation therapy and HER2-targeted therapy compared to HER2-targeted therapy alone for low-risk HER2-positive breast cancer (NCT05705401)

EAY191-N2 (ComboMATCH): Testing the use of fulvestrant and binimetinib targeted treatment for NF1 mutation in hormone receptor-positive metastatic breast cancer

Gastrointestinal Cancer

NRG-GI003: Could Proton Therapy Benefit Patients with Liver Cancer? (NCT03186898)

NRG-GI004: The COMMIT Study: Comparing the Addition of the Drug Atezolizumab to the Usual Treatment Approach for Colorectal Cancer (NCT02997228)

NRG-GI005: The COBRA Study: Using Cancer DNA in the Blood to Predict if Chemotherapy will Benefit Patients who have had Surgery for Early Stage Colon Cancer (NCT04068103)

NRG-GI006: Comparing Proton to Photon Radiation Therapy for Esophageal Cancer (NCT03801876)

NRG-GI007: Is It Safe to Add the Anti-cancer Viral Therapy Telomelysin to Chemoradiation for People with Advanced Esophageal Cancer Who are not Candidates for Surgery? (NCT04391049)

NRG-GI008: CIRCULATE-US: Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (NCT05174169)


Genitourinary Cancer

NRG-GU005: Stereotactic Body Radiotherapy and Prostate Cancer (NCT03367702)

NRG-GU007: A New Anti-Cancer Drug Called Niraparib in Patients with Prostate Cancer (NCT04037254)

NRG-GU008: Does Adding a Study Drug to Usual Therapy After Radical Prostatectomy Delay the Spread of Prostate Cancer? (NCT04134260)

NRG-GU009: Testing Hormone Therapy Treatment to Improve Outcomes for Men with High-risk Prostate Cancer Categorized by Low or High Gene Risk Score (NCT04513717)

NRG-GU010: Can gene risk based on the Decipher risk score inform hormonal therapy treatment with radiation for unfavorable intermediate risk prostate cancer?

NRG-GU011Can the drug relugolix combined with radiation improve outcomes for men with prostate cancer?

NRG-GU012Can adding radiation therapy to the usually prescribed immune therapy increase the time without your renal cell cancer getting worse or requiring surgery?


Gynecologic Cancer

NRG-GY026Can adding trastuzumab or trastuzumab/pertuzumab to the usual treatment for endometrial carcinosarcoma or serous carcinoma prevent your cancer from returning or shrink your cancer?

NRG-GY028Is adding ipatasertib to megestrol acetate better or worse than treatment with megestrol acetate alone?

EAY191-N4 (ComboMATCH): Testing the use of the combination of selumetinib and olaparib or selumetinib alone targeted treatment for RAS pathway mutant recurrent or persistent ovarian and endometrial cancers

Head and Neck Cancer

NRG-HN001:Evaluating individualized treatment for nasopharyngeal cancer based on the patient's dna (nct02135042)

NRG-HN004: Comparing radiation plus durvalumab to radiation plus cetuximab in people with advanced head and neck cancer who cannot take cisplatin (nct03258554)

NRG-HN006: Does sentinel lymph node biopsy improve survival outcomes when compared to elective neck dissection for early stage oral cavity cancer? (nct04333537)

NRG-HN008: Testing the drug peposertib with radiation therapy for people with head and neck cancer that cannot take the chemotherapy drug cisplatin (04533750)

NRG-HN009: Comparing low-dose cisplatin given weekly to high-dose cisplatin given every three weeks when combined with radiation to see if a lower dose given weekly has the same results with less side effects or patient burden

NRG-HN010: Comparing a study drug to the usual treatment for people with metastatic HER2-positive salivary gland cancer that cannot be removed by surgery

NRG-RTOG 1216 (Part 2): Is radiation with docetaxel and cetuximab or radiation with cisplatin and atezolizumab better than usual therapy for high-risk head and neck cancer? (nct01810913)

Lung Cancer

NRG-LU004: Evaluating the safety of durvalumab when added to radiation therapy for locally advanced non-small cell lung cancer (nct03801902)

NRG-LU005: Chemoradiotherapy with or without the immunotherapy drug atezolizumab in people with limited-stage small cell lung cancer (nct03811002)

NRG-LU006: Testing the addition of targeted radiotherapy to surgery and the usual systemic therapy treatment for malignant pleural mesothelioma (MPM) (04158141)

NRG-LU007: Can adding radiation to immune therapy help improve survival for people with extensive stage small cell lung cancer? (nct04402788)

NRG-RTOG 1308: Comparing photon therapy to proton therapy to treat patients with lung cancer (nct01993810)


NRG-CC005 (FORTE): A study to determine whether a colonoscopy should be done every 5 years or every 10 years in people with 1 or 2 small growths (polyps) removed from their colon

NRG-CC007CD: Survivorship care planning for prostate cancer (nct03860961)

NRG-CC008: A study to compare the effects of two surgical procedures in ovarian cancer risk reduction in women with brca1 mutations (nct04251052)

NRG-CC009: Testing two different radiation therapy types to see which is better at preventing loss of memory and thinking ability for people with small cell lung cancer that has spread to the brain


Stay current with science. Sign up for our newsletter.

Support NRG Oncology.
Help Our Cause.

We are a leading protocol organizations within the National Clinical Trials Network and we seek to improve the lives of cancer patients by conducting practice-changing, multi-institutional clinical and translational research. Learn More

Donate Today

NRG Oncology Foundation, Inc, is a nonprofit, tax-exempt foundation. Donations to NRG Oncology help us conduct this important mission, and are tax-deductible to the extent permitted by law.